Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SCTB39-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
SCTB39-1: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
![Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_B_105_21748b7b06.jpg)
9 min read
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals
9 min read
AZD0754 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
AZD0754: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
64Cu-RAX301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
64Cu-RAX301: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ORTHO-R Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ORTHO-R: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
JS101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
JS101: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
4-borono-2-18F-fluoro-phenylalanine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
4-borono-2-18F-fluoro-phenylalanine: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position,
9 min read
Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine(GlaxoSmithKline) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine(GlaxoSmithKline): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development,
9 min read
NP-001 (Novabio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
NP-001 (Novabio): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
EB-DART-NK02 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
EB-DART-NK02: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BMS-986517 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
BMS-986517: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
LEU-011 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
LEU-011: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.